Taisho Signs an Exclusive License Agreement with Moberg Pharma to Develop and Commercialize MOB-015 in Japan
Shots:
- Moberg to receive $5M up front- $50M as development- regulatory & commercial milestone along with supply fees & royalties on sales. Taisho to get exclusive right to develop- register & commercialize MOB-015 in Japan and will fund & conduct development and registration activities in Japan
- The agreement is the third major agreement for MOB-015- validating the market potential of the therapy to treat onychomycosis
- MOB-015 is a topical formulation of Moberg’s terbinafine- being evaluated in P-III study in 800+ patients across North America & EU for 52wks. with 1EPs as complete cure of target nail with its anticipated results in Dec’2019 & Q2’2020 respectively
Click here to read full press release/ article | Ref: PRNewswire | Image: Twitter
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com